Pfizer's Icagen buyout draws investor lawsuit

Law firms began circling Pfizer's $6-a-share buyout deal for Icagen hours after the acquisition left shareholders scrambling to deal with a price that fell well below their expectations. Now Michael Rauscher has emerged as the first investor to get to the courts, filing a claim that the buyout deal--which cost Pfizer close to $50 million for the shares it didn't already own--significantly undervalued the company. More investor suits are expected. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.